Adagio's portfolio of optimized antibodies, including ADG20, is designed to provide durable protection, manufacturability, and affordability. They have secured manufacturing capacity for ADG20 and are developing it for the treatment and prevention of COVID-19. Invivyd is another biopharmaceutical company developing antibodies for viral respiratory diseases, using evolutionary virology, predictive modeling, and antibody engineering to create high-quality, long-lasting antibodies with a high barrier to viral escape. Their goal is to change the paradigm for combatting viral infection by delivering rapid and lasting antibody immunity to protect the general public and ensure vulnerable populations are never left behind.